Kiromic BioPharma, Inc. (KRBPQ)

Kiromic BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1.14	3.2	0.65	25.35	10.15
Cash & Short-Term Investments	1.14	3.2	0.65	25.35	10.15
Cash Growth	-64.51%	396.59%	-97.45%	149.78%	426.18%
Other Receivables	-	-	-	0.02	-
Receivables	-	-	-	0.02	-
Prepaid Expenses	1.51	1.23	1.04	1.7	0.59
Restricted Cash	0.66	-	-	-	-
Total Current Assets	3.3	4.43	1.69	27.07	10.74
Property, Plant & Equipment	5.22	7.72	10.25	3.63	2.07
Other Long-Term Assets	0.02	0.02	0.02	0.03	0.02
Total Assets	8.55	12.17	11.97	30.73	12.83
Accounts Payable	2.68	2.14	7.31	2.21	0.67
Accrued Expenses	3.89	3.16	1.02	0.74	0.33
Short-Term Debt	13.66	14	4.37	0.45	0.47
Current Portion of Leases	0.69	0.63	0.58	-	-
Other Current Liabilities	-	0.45	-	-	-
Total Current Liabilities	20.9	20.38	13.28	3.41	1.47
Long-Term Debt	-	-	2.91	-	-
Long-Term Leases	0.23	0.91	1.54	-	-
Total Liabilities	21.13	21.29	17.74	3.41	1.47
Common Stock	0	0	0	0	0
Additional Paid-In Capital	137.21	113.78	96.17	94.54	52.99
Retained Earnings	-149.8	-122.9	-101.95	-67.22	-41.63
Total Common Equity	-12.59	-9.12	-5.77	27.32	11.36
Shareholders' Equity	-12.59	-9.12	-5.77	27.32	11.36
Total Liabilities & Equity	8.55	12.17	11.97	30.73	12.83
Total Debt	14.57	15.54	9.41	0.45	0.47
Net Cash (Debt)	-13.43	-12.34	-8.77	24.9	9.68
Net Cash Growth	-	-	-	157.16%	401.92%
Net Cash Per Share	-9.19	-11.24	-16.10	65.43	64.47
Filing Date Shares Outstanding	1.53	1.29	0.98	0.52	0.24
Total Common Shares Outstanding	1.53	1.26	0.65	0.52	0.24
Working Capital	-17.6	-15.95	-11.59	23.66	9.27
Book Value Per Share	-8.21	-7.25	-8.91	52.92	46.48
Tangible Book Value	-12.59	-9.12	-5.77	27.32	11.36
Tangible Book Value Per Share	-8.21	-7.25	-8.91	52.92	46.48
Machinery	3.47	3.26	3.18	1.61	0.8
Construction In Progress	0.02	0.1	-	1.23	0.45
Leasehold Improvements	7.37	7.37	7.3	1.46	1.23

Source: S&P Global Market Intelligence. Standard template. Financial Sources.